Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1515445 | 0.84 | SMN1; SMN2 (0.48) | KDM4ESMN1; SMN2EPHX2MAP4K4HRH3 | |
| SCHEMBL8302404 | 0.83 | KDM4E (0.50) | KDM4ESMN1; SMN2EPHX2MAP4K4HRH3 | |
| SCHEMBL17754055 | 0.81 | KDM4E (0.51) | KDM4ESMN1; SMN2EPHX2MAP4K4HRH3 | |
| SCHEMBL1515203 | 0.80 | HPGD (0.49) | KDM4ESMN1; SMN2EPHX2HRH3L3MBTL1 | |
| SCHEMBL17886847 | 0.80 | KDM4E (0.47) | KDM4ESMN1; SMN2EPHX2MAP4K4HRH3 | |
| SCHEMBL14507938 | 0.80 | HRH3 (0.49) | KDM4ESMN1; SMN2EPHX2MAP4K4HRH3 | |
| SCHEMBL8911524 | 0.79 | HPGD (0.55) | KDM4ESMN1; SMN2HRH3L3MBTL1CYP1A2 | |
| SCHEMBL12090211 | 0.79 | MAP4K4 (0.49) | KDM4ESMN1; SMN2EPHX2MAP4K4HRH3 | |
| SCHEMBL25435276 | 0.78 | KDM4E (0.52) | KDM4ESMN1; SMN2HRH3CYP2C19 | |
| SCHEMBL21078309 | 0.78 | KDM4E (0.49) | KDM4ESMN1; SMN2EPHX2MAP4K4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10172845-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180134703-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10172845-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | KDM4E 547/4885SMN1; SMN2 646/4885EPHX2 2451/4885 |
| US-20180134703-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | KDM4E 547/4885SMN1; SMN2 646/4885EPHX2 2451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.